CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 126 enrolled
Drug / intervention
Trazodone +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03534284
NCT03534284Phase 3Completed

Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis (Sleep-HD)

University of Washington·interventional·Posted May 23, 2018·Updated Feb 5, 2024

In Brief

A Phase 3 clinical trial evaluating Cognitive Behavioral Therapy for Insomnia, Trazodone, and 1 other intervention for Insomnia and End Stage Renal Disease. Completed, enrolled 126 participants across 1 site.

Detailed Summary

Insomnia is a common and distressing symptom for patients on hemodialysis (HD), and there is evidence for a much larger impact on the health of patients. Chronic insomnia is disrupted sleep that occurs at least three nights per week and lasts at least three months. The SLEEP-HD study is a randomized open-label clinical trial to compare two types of treatment for insomnia in participants who have end-stage renal disease on HD, and who have been diagnosed with chronic insomnia. The two types of treatment involved in the study are Cognitive Behavioral Therapy for Insomnia (CBT-I) or treatment with a drug (trazodone vs placebo). 126 participants will be enrolled who are undergoing HD in two study locations (Seattle, Washington and Albuquerque, New Mexico).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMay 23, 2018
Enrollment StartSep 19, 2018
Primary CompletionOct 17, 2022
Study CompletionNov 17, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 8.1 years ago

Interventions

Cognitive Behavioral Therapy for Insomniabehavioral

Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.

Trazodonedrug

trazodone tablet

Placebodrug

Inactive pill manufactured to mimic trazodone tablets.